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OBJECTIVES—To comprehensively inventory the proteins that
control the G1/S cell cycle checkpoint in the human islet and
compare them with those in the murine islet, to determine
whether these might therapeutically enhance human -cell rep-
lication, to determine whether human -cell replication can be
demonstrated in an in vivo model, and to enhance human -cell
function in vivo.
RESEARCH DESIGN AND METHODS—Thirty-four G1/S reg-
ulatory proteins were examined in human islets. Effects of
adenoviruses expressing cdk-6, cdk-4, and cyclin D1 on prolifer-
ation in human -cells were studied in both invitro and in vivo
models.
RESULTS—Multiple differences between murine and human
islets occur, most strikingly the presence of cdk-6 in human
-cells versus its low abundance in the murine islet. Cdk-6 and
cyclin D1 in vitro led to marked activation of retinoblastoma
protein phosphorylation and cell cycle progression with no
induction of cell death. Human islets transduced with cdk-6 and
cyclin D1 were transplanted into diabetic NOD-SCID mice and
markedly outperformed native human islets in vivo, maintaining
glucose control for the entire 6 weeks of the study.
CONCLUSIONS—The human G1/S proteome is described for
the ﬁrst time. Human islets are unlike their rodent counterparts
in that they contain easily measurable cdk-6. Cdk-6 overexpres-
sion, alone or in combination with cyclin D1, strikingly stimulates
human -cell replication, both in vitro as well as in vivo, without
inducing cell death or loss of function. Using this model, human
-cell replication can be induced and studied in vivo. Diabetes
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R
ecent reports demonstrate that human islet
transplantation is technically feasible (1,2), that
replication is a major means of maintaining
-cell numbers in rodents, and that all rodent
adult -cells are capable of replicating (3–5). In addition,
advances in understanding the signaling pathways and
growth factors that can induce -cell replication continue
to accrue (6–13). It is now clear that both type 1 and type
2 diabetes result from a decline in -cell mass (14–16).
Collectively, these observations underscore a need to
understand, and to therapeutically exploit the molecular
mechanisms underlying -cell replication and regenera-
tion. Abundant data in mice have demonstrated that the
“G1/S checkpoint,” or the “G1/S pathway” (supplemental
Fig. 1, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-0631/DC1), in the
cell cycle is critical in regulating rodent -cell replication and
physiological function (rev. in 17–26).
In contrast to this richness in knowledge regarding
-cell cycle control in the mouse, relatively little is known
regarding cell cycle control in the human islet (17,23,26).
This is important because the fundamental reason for
studying -cell replication is to leverage such knowledge
for expanding functional human -cell mass for the treat-
ment or prevention of diabetes. Signiﬁcantly, whereas
abundant examples exist for robust induction of rodent
-cell replication (3–6,9–13,17–19,27,28), multiple reports
suggest that in contrast to rodents, human -cell replica-
tion is a rare event; indeed, several authors have reported
that they cannot demonstrate replication in human -cells
either under basal conditions or in response to growth
factors (15,17,29–31).
We therefore sought to catalog in the human islet the
molecules that control the G1/S checkpoint of the cell
cycle. We report such a G1/S roadmap and compare it with
that of the murine islet. We demonstrate that whereas
cdk-6 is difﬁcult to detect or absent in murine -cells, it is
present in human -cells. Furthermore, we show that
cdk-6 and a D-cyclin partner can be used to markedly
accelerate replication in human -cells in vitro. Most
importantly, we show that combined overexpression of
cdk-6 with cyclin D1 also leads to human -cell replication
in vivo and results in enhanced human islet engraftment
and function in an in vivo transplant diabetes model.
RESEARCH DESIGN AND METHODS
Human islets. Human islets were obtained through the National Institutes of
Health– and Juvenile Diabetes Research Foundation–supported Islet Cell
Resource Consortium (http://icr.coh.org). On arrival, human islets were
washed with PBS and incubated in RPMI medium (Gibco, Grand Isle, NY)
containing 5.5 mmol/l glucose, 1% penicillin, and streptomycin with 10% FBS
until they were used for experiments. Receipt of, and work with, human islets
was approved in advance by the University of Pittsburgh Institutional Review
Board.
Immunoblotting and RT-PCR. Human and animal islet extracts were
prepared within 24–48 h of arrival using nuclear extract buffer resolved using
7.5–15% SDS-PAGE depending on the molecular weight of the protein in
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882 DIABETES, VOL. 58, APRIL 2009question and then transferred to Immobilon-P membranes (Millipore, Brad-
ford, MA) as we have described previously (23,24). Primary antisera and
dilutions used are shown in supplemental Table 1 (available in the online
appendix). Each immunoblot was performed a minimum of three times on a
minimum of three different islet preparations, each accompanied by an
appropriate housekeeping protein control, either tubulin or actin. Represen-
tative immunoblots and actin/tubulin controls are shown in Figs. 1–8. RT-PCR
for cdk-4 and cdk-6 were preformed as described previously (9,13,22,23) using
primers described in the legend to Fig. 1.
Human -cell proliferation, cell death, and glucose-stimulated insulin
secretion in vitro. Human islet cell proliferation was assayed as reported
previously (23) with the exception that the islets were labeled with bromode-
oxyuridine (BrdU) for the ﬁnal 24 h using a 1:1,000 dilution of BrdU (Sigma)
and stained for BrdU and insulin as described subsequently for in vivo
staining. Propidium iodide was used for nuclear staining and visualization of
pyknotic nuclei. Glucose-stimulated insulin secretion was performed as
described previously (23).
Quantiﬁcation of transplanted human -cell proliferation in vivo. -Cell
proliferation was assessed in vivo in renal grafts as described previously
(9,23–25,32) with the following modiﬁcations. Graft-containing kidneys were
harvested on the third day after transplantation, 6 h after BrdU injection, ﬁxed
in 4% paraformaldehyde overnight at 4°C, parafﬁn-embedded, and sectioned.
In the graft-containing kidneys, three serial sections separated by 25 m were
deparafﬁnized, rehydrated, and treated in prewarmed 1M HCl for1ha t37°C,
blocked in 2% BSA/PBS for 1 h, then incubated overnight with anti-BrdU
(Abcam, Cambridge, MA) and anti-insulin antibodies (Zymed, San Francisco,
CA). After serial washing in PBST, slides were incubated for 1 h with
secondary antibodies, gel-mounted, and coverslipped. Two sections per graft
were analyzed. Three ﬁelds per section were quantiﬁed for BrdU- and
insulin-positive cells.
Immunocytochemistry and laser confocal microscopy. For cdk-6 immu-
nohistochemistry, human islets were ﬁxed in 2% paraformaldehyde for 12 min
at room temperature followed by three 5-min washes in PBS. Islets were then
blocked in 1 PBS, 0.2% Triton-X-100, 0.1 mmol/l CaCl, with 2% fetal bovine
serum for1ha troom temperature. Primary antibodies (supplemental Table 1,
available in the online appendix) were used at 20°C overnight. Secondary
antibodies were incubated for1ha troom temperature. After three 5-min
washes in PBS, islets were placed on microscope slides, coverslipped in
antifade gel mount, and stored in the dark at 20°C. Islets were imaged using
an Olympus Fluoview 1000 laser confocal microscope.
Adenoviruses. Adenoviruses expressing human cyclin D1, human cdk-4
(Ad.hcdk-4),  galactosidase (Ad.lacZ), and green ﬂuorescent protein driven
by the CMV promoter were described previously (23). Adenovirus expressing
human cdk-6 was prepared as described (23). Multiplicity of infection (MOI)
were deﬁned as in the past (23), and duration of exposure used is detailed in
the ﬁgure legends.
Human islet marginal mass model in NOD-SCID mice. Human islets were
transplanted under the renal capsule of streptozotocin-induced diabetic
NOD-SCID mice as described in detail previously (6,9,32,33). One islet
equivalent (IEQ) was deﬁned as 125 m. All transplant studies with human
islets in the streptozotocin-induced diabetes model were approved by, and
performed in accordance with, the University of Pittsburgh Institutional
Animal Care and Use Committee. Intraperitoneal glucose tolerance tests
(IPGTTs) were performed as described previously (9,13,24,25).
For the BrdU and propidium iodide experiments, Student’s unpaired
two-tailed t-test was used. For the marginal mass NOD-SCID transplant model,
one-way ANOVA for repeated measures was performed. P values 0.05 were
considered signiﬁcant.
RESULTS
The results of a screen for each of the G1/S regulatory
molecules using protein extracts from human islets are
shown in Fig. 1. In each of the panels, results are shown
for two different, but representative, human islet extracts,
labeled H1 and H2. As can be seen in Fig. 1A, each of the
three members of the so-called “pocket protein family,”
pRb, p107, and p130, are present in human islets. The
pocket proteins regulate cell cycle progression by binding
to the E2F family of transcription factors, which in turn
regulate the expression of the myriad genes required for
cell cycle progression. Figure 1B demonstrates that human
islets contain E2Fs 1, 3, 4, and 7 but not E2Fs 2, 5, and 6.
The pocket proteins are phosphorylated by two kinase
complexes, the cdks and their cyclin partners. Figures 1C
and D demonstrate that human islets contain all three D
cyclins, and easily measurable cyclin E, with less abun-
dant, or at least less easily detectable, cyclin A. In addition,
human islets contain easily demonstrable cdk1 (also called
cdc2) and cdk2, the cognate partners of cyclins A and E.
We had preliminarily reported that human islets lack
cdk-4 based on studies using antisera from Abcam and
Santa Cruz and appropriate positive and negative controls
(34). However, we were able to observe cdk-4 immunore-
activity using a third cdk-4 antiserum (cdk-4 in Fig. 1D).
To be certain that the cdk-4 immunoblots accurately
reﬂected endogenous cdk-4 and not cross-reactivity with
another cdk or other protein, we adenovirally overex-
pressed human cdk-1, cdk-2, cdk-4, and cdk-6 in human
islets and performed immunoblotting using three different
commercially available cdk-4 antisera. As can be seen in
Fig. 1H, the Abcam 3112 and Santa Cruz 749 antisera failed
to detect cdk-4 in human islets, although cdk-4 immuno-
reactivity was readily visible by both antisera when cdk-4
was overexpressed. In contrast, cdk-4 was easily observed
in normal human islet preparations under basal conditions
using the Santa Cruz 260G antiserum, and this was en-
hanced by overexpression of cdk-4 but not by overexpres-
sion of cdk-1, cdk-2, or cdk-6. These observations suggest
that the three cdk-4 antisera do not cross-react with other
cdks and that authentic cdk-4 is indeed present in human
islets, but at sufﬁciently low levels that it is only observ-
able using the third cdk-4 antiserum. RT-PCR and sequenc-
ing of the ampliﬁed cDNA products conﬁrmed that human
cdk-4 mRNA in present in human islets (Fig. 1I).
Surprisingly, in marked contrast to results in murine
islets (17,23,35,36), human islets contain the cdk-4 ho-
molog cdk-6 (Fig. 1D). To conﬁrm that the cdk-6 immuno-
blot accurately reﬂected the presence of cdk-6 in human
islets, we performed immunoblots using three different
cdk-6 antisera, as shown in Fig. 1H. As can be seen in the
ﬁgure, cdk-6 was observed in each of the human islet
preparations with each of the three antisera used, and in
each case, there was a speciﬁc increase in expression after
transduction with Ad.cdk-6. Moreover, cdk-6 immunoreac-
tivity was not enhanced by overexpression of cdk-1, cdk-2,
nor cdk-4, indicating speciﬁcity of the antisera for cdk-6.
RT-PCR and sequencing of the ampliﬁed cDNA products
conﬁrmed that human cdk-6 mRNA is present in human
islets (Fig. 1I).
Upstream of the cdks and cyclins are two families of cell
cycle inhibitors, the INK4 family and the CIP/KIP/WAF
family. As can be seen in Figs. 1E and F, each of the four
INK4s and each of the three CIP/KIP/WAF family members
is easily detectable in human islets. Finally, Fig. 1G shows
a number of additional G1/S regulatory molecules that are
involved in cell cycle control.
To independently conﬁrm the mentioned immunoblot
studies, and to determine whether cdk-6 was present
speciﬁcally in human -cells, we performed immunohisto-
chemistry for cdk-6. The upper row of Fig. 2A demon-
strates that cdk-6 is absent or at least undetectable in rat
islets. The middle row of this ﬁgure is a positive control
and demonstrates that when human cdk-6 is expressed in
rat islets using Ad.cdk-6, it is now easily observed in rat
islets. These ﬁndings demonstrate that human cdk-6 can
be reliably assessed using these immunohistochemistry
techniques. The bottom row of Fig. 2A shows that native,
nontransduced human islets contain easily measurable
cdk-6 and that cdk-6 is present in the cytosol in -cells.
Interestingly, cdk-6 appears almost exclusively in the
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DIABETES, VOL. 58, APRIL 2009 883FIG. 1. Immunoblots for the G1/S control molecules in the human islet. Each panel represents two examples of immunoblots of human islet
extracts, and each is representative of at least three, and as many as eight, human islet preparations. Islets were extracted between 24 and 48 h
of arrival. Antisera are shown in supplemental Table 1 of the online appendix. A: The pocket proteins. B: E2F family. C: Cyclin family. D: cdk
family (cdk-4 and cdk-4 represents immunoblots preformed with Abcam and sc-260G antisera as explained in H). E: INK4 family. F: KIP/CIP/WAF
family. G: Miscellaneous other G1/S molecules (note that HDM2 is the human homolog of murine MDM2, the ubiquitin ligase for p53). H: Results
obtained with multiple cdk-4 and cdk-6 antisera. To deﬁne the speciﬁcity of several available cdk-4 and cdk-6 antisera, human islets were
transduced with adenoviruses (250 MOI) encoding cdk-1, cdk-2, cdk-4, and cdk-6 for 1 h, incubated for 48 h, and then extracted, resolved on
SDS-PAGE, and immunoblotted for the six antisera shown. As can be seen, none of the cdk-4 or cdk-6 antisera cross-reacted with cdk-1, cdk-2,
cdk-4, or cdk-6, and each was upregulated by the cognate cdk. All three cdk-6 antisera recognized cdk-6 in normal nontransduced islets, but only
the sc-260 cdk-4 antiserum was able to detect cdk-4 in normal human islets. I: RT-PCR for cdk-4 and cdk-6 in human islets. MR indicates molecular
weight markers, and H2O indicates a lane with no polymerase. Human osteosarcoma cells (SaOS2) and the human kidney cell line HK2 are positive
controls. Sequencing of the ampliﬁed PCR products conﬁrmed the presence of human cdk-4 and cdk-6. The primers used spanned intron–exon
boundaries and generated products of the expected size: 484 bp for cdk-4 (vs. 754 for the genomic product) and 341 bp (vs. 8,457 for the genomic
product). The primers used were: cdk-6 5-GGCGCCTATGGGAAGGTGTTC-3;5 -AAAGTCCAGACCTCGGAGAAGC-3; cdk-4 5-GTGGCTGAAAT-
TGGTGTCGG-3;5 -GCCATCTGGTAGCTGTAGATTC-3.
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These results are conﬁrmed by higher-power magniﬁca-
tion of human -cells (Fig. 2B).
The preceding studies demonstrate that human islets
contain cdk-6 but shed no functional light on whether
cdk-6 drives cell cycle progression. To study cdk-6 func-
tion, we transduced human islets with adenoviruses ex-
pressing cdk-4 and cdk-6 alone or in combination with
cyclin D1. As shown in Fig. 3A, the transductions were
effective with each of the viruses leading to overexpres-
sion of the appropriate G1/S control protein. As can be
seen in Fig. 3B, cyclin D1 and cdk-6 alone were able to
phosphorylate pRb as were the combinations of cyclin D1
plus cdk-4 or cyclin D1 plus cdk-6.
These ﬁndings would suggest that the cdk-6/cyclin D1
combination might lead to proliferation of -cells. To
assess this, human islets were transduced with the com-
binations of viruses shown in Fig. 4A, and proliferation
was assessed in human -cells 3 days following transduc-
tion. As can be seen in the ﬁgure, BrdU-positive cells were
FIG. 2. Confocal immunohistochemistry for cdk-6 in rat and human islets. A: In the upper panel, as a negative control, rat islets that do not
contain cdk-6 were stained for insulin (red) or cdk-6 (green). Cdk-6 is not detectable in rat islets. In the middle panel, when rat islets are
transduced with Ad.cdk-6 as a positive control, cdk-6 immunoreactivity is easily observed. In the lower panel, when human islets are stained for
cdk-6, immunoreactivity is easily observed and colocalizes with insulin-positive cells. B: A higher-power magniﬁcation demonstrates that cdk-6
is present in the cytoplasm of human -cells. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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human islets transduced with Ad.lacZ or cdk-4. In con-
trast, BrdU incorporation was regularly observed in hu-
man -cells transduced with Ad.cdk-6 alone, Ad.cyclin D1
alone, or combinations of Ad.cdk-4 or Ad.cdk-6 plus
Ad.cyclin D1. These results are quantiﬁed in Fig. 4B where
it can be seen that overexpression of cdk-6 plus cyclin D1
induced a dramatic increase in proliferation with the
combination leading to 13% of -cells incorporating BrdU
as compared with 0.3% under basal conditions or after
Ad.lacz transduction, an approximate 40-fold increase in
proliferation. BrdU incorporation occurs in cells other
than -cells (Fig. 4A). As shown in supplemental Fig. 2
(available in the online appendix), immunohistochemistry
for insulin, glucagon, and somatostatin revealed few
BrdU
 cells, suggesting that the remaining BrdU
 nonin-
sulin
 cells in Fig. 4A are likely ﬁbroblasts and endothelial,
ductal, residual acinar, and other cell types transduced
with Ad.cyclin D1-cdk-6 driven by the generalized CMV
promoter.
To determine whether the -cell proliferation was sus-
tained for longer than 3 days, the experiments in Fig. 4A
were repeated and proliferation assessed 10 days after
transduction. As shown in Fig. 4C and D, BrdU incorpora-
tion in Ad.lacZ-transduced -cells was 1.6% as compared
with 7% in islets transduced with Ad.cdk-6 plus cyclin
D1, indicating that cyclin-cdk–driven proliferation can be
sustained for at least 10 days in vitro.
To determine whether the combinations of cell cycle
activators also activated cell death in human -cells, we
performed propidium iodide staining and examined nu-
clear pyknosis as a measure of cell death. As can be seen
in Fig. 5A and B, cell death represented by nuclear
pyknosis was common among -cells under basal condi-
tions as well as following cell cycle activation by cdk-6 and
cyclin D1, but there were no differences among the groups.
These ﬁndings were conﬁrmed by measuring cleaved
caspace-3 in islets transduced with Ad.cdk-6 and cyclinD1
in the several combinations shown in Fig. 5C and D.
To determine whether transduction with cdk-6 plus
cyclin D1 might result in dedifferentiation of -cells, or loss
of -cell function, we examined glucose-stimulated insulin
secretion studies at days 3 and 10 after transduction. As
can be seen in Fig. 6, glucose-stimulated insulin secretion
remained robust at both days 3 and 10.
Combined overexpression of cdk-6 and cyclin D1
enhances human islet engraftment, proliferation, and
function in vivo. To determine whether the proliferative
effects of cdk-6 and cyclin D1 observed in vitro might
translate to enhanced islet engraftment and function in the
in vivo setting, we used the marginal mass model of human
-cell engraftment (6,9,32,33). As can be seen in Fig. 7A,
sham-transplanted NOD-SCID mice induced to develop
diabetes using streptozotocin remained hyperglycemic in
the 450–500 mg/dl range for the 6-week duration of the
experiment (negative control). In contrast, mice trans-
planted with 4,000 human IEQ (positive control) displayed
random postprandial blood glucose values in the 150–160
mg/dl range. However, 1,500 nontransduced IEQ or 1,500
human islet IEQ transduced with Ad.LacZ caused only a
mild attenuation in hyperglycemia in the 350–400 mg/dl
range and therefore constituted an ideal marginal mass.
Importantly, 1,500 IEQ transduced with Ad.cdk-6 plus cyclin
D1 performed in a fashion far superior to the 1,500 IEQ
controls and were indistinguishable from 4,000 human IEQ,
indicating an approximate threefold enhancement of cdk-6/
cyclinD1–transduced islets over controls. This improvement
in blood glucose was sustained for the entire 6 weeks of the
study but was reversed by unilateral nephrectomy.
To more rigorously deﬁne graft function in vivo, we
performed IPGTTs on mice 14–21 days after islet trans-
plant. As shown in Fig. 7B, streptozotocin-induced
diabetic NOD-SCID mice treated with sham or with
1,500 IEQ of Ad.lacZ-transduced grafts were markedly
glucose intolerant. In contrast, normal NOD-SCID mice
displayed excellent glucose tolerance as did streptozo-
tocin-induced diabetic animals transplanted with 4,000
IEQ. Interestingly, diabetic animals transplanted with
1,500 IEQ transduced with Ad.cdk-6 plus cyclin D1
behaved similarly to normal NOD-SCID mice and to
diabetic NOD-SCID mice transplanted with 4,000 IEQ.
Furthermore, fasting glucose levels in the cdk-6 plus
cyclin D1 group were 60 mg/dl and comparable with
FIG. 3. The effect of overexpression of cdk-4, cdk-6, and cyclin D1 on phosphorylation of the retinoblastoma protein, pRb. A: cdk-4, cdk-6, and
cyclin D1 were overexpressed in human islets by their cognate virus but not in human islets transduced with Ad.lacZ or in normal human islets.
As assessed using densitometry, cdk-4 was overexpressed 9.8-fold, cdk-6 5.5-fold, and cyclin D1 24.8-fold. B: Transduction of human islets with
Ad.cdk-6, Ad.cyclin D1, or combinations of Ad.cdk-4 plus Ad.cyclin D1 or Ad.cdk-6 plus Ad.cyclin D1 leads to phosphorylation of endogenous pRb.
This does not occur in the relevant controls or with Ad.cdk-4 alone. In all experiments, 500 MOI was used for 1 h with, for example, 250 MOI of
Ad.lacZ plus 250 MOI of Ad.cdk-6 in lanes that contained a single cell cycle activator or 500 MOI of Ad.lacZ in which no cell cycle activator was
included. Extracts were prepared and immunoblots performed 3 days after transduction.
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planted with 4,000 IEQ.
To determine whether -cell proliferation continued
in vivo after transplantation of human islets, we re-
peated these experiments, this time sacriﬁcing the
transplant recipients at 3 days after transplantation
after in vivo labeling with BrdU. As can be seen in Fig.
8A and B, BrdU incorporation into -cells was abundant
and easily observable in the cdk-6/cyclin D1 grafts in
vivo. This was in marked contrast to sections from the
control grafts in which little or no proliferation was
observed in -cells. These results are quantiﬁed in Fig.
8C, in which nine of 4,829 control graft -cells (0.2%)
were BrdU-positive as compared with 147 of 3,115
A
B CD
FIG. 4. Induction of proliferation by cdk-4, cdk-6, and cyclin D1. A: Examples of isolated human islets stained for insulin (green) and BrdU (red)
3 days after transduction with adenoviruses encoding cdk-6 plus cyclin D1. B: Quantiﬁcation of the BrdU incorporation into -cells under each
of these conditions. Bars represent SE. “# BrdU/insulin” refers to the number of cells that are positive for BrdU and insulin as a function of the
total number of -cells counted. “HP samples” refers to the numbers of human pancreatic islet samples examined. “# sections” refers to the
number of tissue sections examined. “# ﬁelds” refers to the number of high-powered microscope ﬁelds examined. LZ, Ad.lacZ; D1, Ad.cyclin D1;
C4, Ad.cdk-4; C6, cdk-6. The total MOI used for each experiment was 500, and where combinations were used, for example, “D1,” 250 MOI of each
Ad.cyclin D1 and Ad.lacZ. C–D: Studies in isolated cultured human islets were similar to those in A and C but were studied 10 days after
transduction with BrdU labeling for the ﬁnal 24 h before harvesting the islets. The colored numbers within the bars indicate the absolute numbers
of BrdU
 and insulin
 cells. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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ence was highly signiﬁcant.
To assess survival of human -cells after transduction
and engraftment, we examined transferase-mediated
dUTP nick-end labeling (TUNEL) staining in these same
human grafts in Fig. 8D and E obtained 3 days after
engraftment. As can be seen in Fig. 8F, 2% of Ad.lacZ and
Ad.cdk-6/cyclin D1–transduced -cells were TUNEL-posi-
tive at day 3 after transplant.
DISCUSSION
Whereas many studies have demonstrated that rodent
-cells replicate (3–6,9–13,17–19,27,28), most investiga-
FIG. 5. Cell death in human islets transduced with cdk-4, cdk6 and
cyclin D1. Abbreviations are the same as in Fig. 4. A: Isolated human
islets costained with propidium iodide (red) islets and anti-insulin
antisera (green) 3 days after adenoviral transduction. Arrows illus-
trate pyknotic nuclei that are comparable among the several condi-
tions. B: Quantiﬁcation of these data. Cell death rates are high in
cultured human islets but were not exacerbated by cdk-6, cyclin D1,o r
the combination. C: An immunoblot for cleaved caspace-3 in the
several groups 3 days after adenoviral transduction. D: The densi-
tometric quantiﬁcation of six such experiments. Bars indicate
means  SEM. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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vivo is a rare event (15,17,29–31). We had previously
catalogued the molecules that control the G1/S transition
in the murine islet (17,23,24). Because of the central role of
the G1/S transition in -cell cycle control, because of the
reported differences in the rates of -cell proliferation
rates in human versus rodent -cells, and in light of the
need to develop a means of enhancing human -cell
regeneration, we analyzed the molecules that control the
G1/S checkpoint in the human islet.
We ﬁnd that in contrast to murine islets which contain
little or no cdk-6 (17,23,35,36), each of the four G1/S
cyclins and cdks is present in the human islet. In particu-
lar, cdk-6, an activator of cell cycle progression in many
cell types, is abundant in human islets and speciﬁcally
within the -cell. The inability to detect cdk-6 in murine
islets and the central role of cdk-4 in murine islets are
supported by the observations that cdk-4 appears to be the
downstream mediator of -cell proliferation induced by
the IRS-1–PI3 kinase pathway in murine -cells (8) that
knockout of cdk-4 leads to severe -cell attrition and
neonatal diabetic ketoacidosis in mice (21), whereas cdk-6
knockout mice display no -cell phenotype but instead
have severe hematologic abnormalities (36). Our observa-
tions suggest that although cdk-4 is essential to murine
islet development and function, cdk-4 in human islets is
likely redundant with cdk-6, which may play a similar and
complimentary role in human -cells.
In functional terms, overexpression of cdk-6 in combi-
nation with cyclin D1 leads to uniquely robust proliferation
FIG. 6. Glucose-stimulated insulin secretion (GSIS) in isolated human islets transduced with cdk-6 and cyclin D1. GSIS was studied at either 3
days (A) or 10 days (B) after transduction. Five different human islet preparations were used for each panel. Insulin secretion was determined
using a human insulin ELISA kit (Alpco). Bars indicate mean  SEM. Abbreviations are the same as in Fig. 4.
FIG. 7. Cdk-6 and cyclin D1 enhance human islet function in vivo in streptozotocin-induced diabetic NOD-SCID mice. Bars indicate mean  SEM.
A: Sham-transplanted mice and mice transplanted with 1,500 IEQ alone or 1,500 IEQ transduced with Ad.lacZ are shown in the black lines as
described in the key within the ﬁgure. Mice transplanted with 1,500 IEQ transduced with Ad.cdk-6 plus Ad.cyclinD1 are shown in green and
compared with 4,000 normal, nontransduced IEQ. UNX, unilateral nephrectomy. The numbers in the key refer to the number of experimental
animals in each group. The characteristics of the donor islets as provided by the ICRC procurement centers were as follows: average age  SEM
42.8  2.1 years (range 20–66), average viability 88.7%  1.4%, and average purity 77.9%  2.2%. B: Intraperitoneal glucose tolerance testing
in normal (nondiabetic) NOD-SCID mice, sham-transplanted streptozotocin-induced diabetic NOD-SCID mice, diabetic NOD-SCID mice
transplanted with 4,000 IEQ human islets, 1,500 human IEQ transduced with Ad.lacZ, or 1,500 IEQ transduced with 1,500 IEQ expressing cdk-6
plus cyclin D1. Studies were performed 14–21 days following transplantation. The numbers in parentheses indicate the numbers of animals
studied.
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cdk-4 overexpression in combination with cyclin D1 in
human -cells led to an approximate ninefold increase in
proliferation (23). However, these studies were limited
entirely to in vitro observations for 48–72 h. We report that
a second combination of cell cycle activators (cdk-6 in
combination with cyclin D1) can induce an even greater
stimulation in human -cell replication—for some, 40-fold.
Furthermore, unlike cdk-4 overexpression, which alone is
unable to either measurably phosphorylate pRb or activate
-cell replication (23) (Fig. 3B), cdk-6 overexpression
alone is able to accomplish both of these outcomes,
presumably by combining with endogenous -cell D-type
cyclins. Furthermore, as we previously reported for the
cdk-4/cyclin D1 combination (23), cell death was not
activated in human -cells by the cdk-6/cyclin D1 combi-
nation. Future studies will be required to deﬁne whether
cdk-6 alone will prove as effective in vivo as when supplied
in combination with cyclin D1.
Perhaps the most critical observation in the current
study is that, unlike prior in vitro studies with human islets
and human autopsy specimens in which human -cell
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FIG. 8. Effects of cdk-6 and cyclin D1 on -cell proliferation and cell death in vivo. A–B: Proliferation in human -cells in vivo 3 days after
transduction and transplantation. BrdU is shown in red and -cells are shown in green. Three grafts (three each from Ad.lacZ or Ad.cdk-6/
cyclinD1) of human islets were removed by unilateral nephrectomy at day 3 after transduction (day 2 after transplantation) and examined for
proliferation. The expanded boxes show examples of BrdU-positive -cells. C: Quantiﬁcation of BrdU-positive insulin-positive cells as a function
of total insulin-positive cells. The numbers shown within the bars indicate the number of BrdU-positive (red) -cells and of insulin-positive
(green) cells. The numbers below the bars indicate the numbers of animals studied with two sections per animal. D and E: TUNEL staining in
human islets at 3 days after transplantation. These are the same grafts as shown in A–C. F: Quantiﬁcation of TUNEL staining in D and E in vivo
3 days after adenoviral transduction and transplantation. Labels are the same as in Fig. 4D. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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human -cell replication can be documented and quanti-
ﬁed in vivo for the ﬁrst time using the NOD-SCID human
islet transplant model described here. In addition, the
whole-animal glucose and insulin metabolic axis can si-
multaneously be monitored. Although the diabetic NOD-
SCID mouse model is not novel, its use to document
accelerated human -cell replication is. This human islet
transplant model is important, because it will permit
investigators to ask for the ﬁrst time, using human islets,
whether interventions such as glucose infusion (37), diet-
induced obesity (20), lipid infusion (38), pregnancy (27),
or treatment with growth factors or drugs such as GLP-1,
exenatide, gastrin, EGF, or others (9–13) can lead to
activation of human -cell replication in vivo.
In addition to the studies centered on cdk-6, the human
G1/S proteome reveals a variety of additional novel obser-
vations. For example, human islets, like their murine
counterparts, contain all seven INK4 and CIP/KIP/WAF
family members, all three pocket proteins, menin, and p53.
That is, every single cell cycle inhibitor that might be
present in any cell type is present in the human islet; if one
wanted to design a cell type that could not possibly
replicate, this is how it would be accomplished. Their
simple presence of course does not prove function, but
this model will also allow further detailed in vivo study.
For example, physiological and therapeutic activation of
cell cycle progression in human -cells, like their murine
counterparts (19–26), might be accomplished by knock-
down or silencing of individual or combinations of cell
cycle inhibitors such as menin, p18 and p27, or pRb
and p53.
Another novel observation is that human islets contain
all three pocket protein members, pRb, p107, and p130;
previously, only pRb has been identiﬁed in human islets
(23). As another example, human islets lack E2F2, a
protein that is present in murine islets (17,23,24) and the
loss of which in knockout mice leads to severe pancreatic
exocrine and endocrine dysfunction (39,40). Similarly,
human islets contain E2F3 and E2F7, whereas their mu-
rine counterparts lack both E2F3 and E2F7 (17,23,24). The
functional and therapeutic implications of these observa-
tions are currently unknown but clearly merit further
exploration.
A number of additional important questions remain for
future studies. One important question relates to the
quantiﬁcation of -cell mass loss or accrual in this model.
It would be ideal to be able to accurately assess -cell
mass as well as -cell differentiation. However, this will be
challenging given the complex mixture of cell types con-
tained in islet grafts (6,32,41). Potential approaches to
quantitate increments in -cell mass might include intraoc-
ular anterior chamber transplant (42) or combining insulin
promoter-driven viral delivery of luciferase with external
imaging coupled with graft histomorphometry.
It is also important to emphasize that the immunoblots
describing the human G1/S proteome were performed on
whole human islets, which are comprised predominantly
of non--cells. Thus, for the cell cycle proteins described
(other than cdk-4 and cdk-6, which were conﬁrmed to be
present in the -cell using immunohistochemistry), future
studies will need to unequivocally document the presence
or absence of these molecules in human -cells.
Another important question relates to the duration of
the adenovirus expression and -cell replication induced
by cdk-6/cyclin D1. We have examined only a single early
time point, but it is important to know whether adenoviral
expression is sustained for the entire 6 weeks of the
experiment or even longer. In this regard, we have recently
demonstrated, using a similar model, that adenoviral ex-
pression of hepatocyte growth factor in transplanted pri-
mate islets persists for at least 6 weeks (43).
Although we show that cdk-6 overexpression is able to
activate the -cell cycle, this does not address the physi-
ological role of cdk-6 in the human -cell nor mechanisms
through which it acts. Further studies will be required to
deﬁne the consequences of cdk-6 loss on human -cells
and to identify the cyclin INK/KIP/CIP partners of cdk-6.
This is particularly interesting in that the large majority of
cdk-6 is present in the cytosolic compartment, not the
nuclear compartment where it might phosphorylate
pocket proteins. Is cdk-6 a cytosolic protein only in resting
-cells that translocates to the nucleus in proliferating
-cells? Or does cdk-6 always remain in the cytoplasm?
Can it drive cell cycle progression by sequestering CIPs/
KIPs in the cytoplasm away from cdk-1/cdk-2 cyclin A/E
complexes? Answering these questions and others will
require puriﬁcation of human -cells, coimmunoprecipita-
ton, colocalization, live-cell imaging, and other studies. In
addition, whether cdk-6 expression or activity is regulated
by growth factors and signaling pathways in human islets,
as is cdk-4 in the murine islet (8), provides fertile ground
for future study.
Finally, cdks and cyclins are oncogenes. This raises the
question as to whether sustained therapeutic cdk or cyclin
activation might have oncogenic consequences. On the
“high oncogenic risk” side of the equation, cdk-4 is asso-
ciated with melanoma and other malignancies and cyclin
D1 with insulinomas, breast cancer, and lymphomas (44–
46). On the “low oncogenic risk” side of the equation, these
cell cycle molecules of course are also normal regulators
of cell cycle replication in all cells, including -cells. Under
normal physiological circumstances, their level of expres-
sion is tightly controlled and does not lead to tumor
development but sufﬁces to expand -cell mass in embry-
ology and childhood. Thus, if it were possible to control
the duration and degree of expression of these molecules
through the use of -cell–speciﬁc and regulatable promot-
ers, their degree and duration of activation might be
engineered to mimic physiological -cell replication and
expansion. Because the islet grafts can be left in place
for months or even 1 or 2 years, the model described
here will permit accurate and meaningful study of their
oncogenicity.
In summary, we have provided a human -cell cycle
“G1/S proteome,” which can serve as a road map or model
to more deeply understand and exploit human -cell
replication. We have also developed an in vivo model in
which to explore the function of these molecules as well
as a broad variety of physiological maneuvers on human
-cell replication. We have also demonstrated a variety of
other unanticipated differences between rodent and hu-
man G1/S regulatory machinery. Collectively, these studies
make three fundamental points. First, rodent studies
aimed at augmenting human -cell replication need to be
conﬁrmed in human islets; if one wants to understand
human -cell replication, one will need also to study
human -cells. Second, although progress is being made in
understanding the molecular details of cell cycle control in
the pancreatic -cell, current understanding is still rudi-
mentary. Third, it is clearly possible to drive human -cell
replication in ways that retain differentiation and function
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proaches designed to exploit fundamental cell cycle con-
trol in human -cells may provide insight into how best to
expand human -cells for therapeutic purposes in the
treatment of diabetes.
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